Table of Contents
International Journal of Peptides
Volume 2012 (2012), Article ID 349427, 6 pages
http://dx.doi.org/10.1155/2012/349427
Research Article

Infection by CXCR4-Tropic Human Immunodeficiency Virus Type 1 Is Inhibited by the Cationic Cell-Penetrating Peptide Derived from HIV-1 Tat

Department of Microbiology and Immunology, Center for Molecular Virology and Translational Neuroscience, and Center for Sexually Transmitted Disease, Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, Philadelphia, PA 19102, USA

Received 30 June 2011; Revised 15 October 2011; Accepted 25 October 2011

Academic Editor: Lloyd D. Fricker

Copyright © 2012 Shawn Keogan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Foerg, K. M. Weller, H. Rechsteiner et al., “Metabolic cleavage and translocation efficiency of selected cell penetrating peptides: a comparative study with epithelial cell cultures,” American Association of Pharmaceutical Scientists Journal, vol. 10, no. 2, pp. 349–359, 2008. View at Publisher · View at Google Scholar
  2. I. Nakase, T. Takeuchi, G. Tanaka, and S. Futaki, “Methodological and cellular aspects that govern the internalization mechanisms of arginine-rich cell-penetrating peptides,” Advanced Drug Delivery Reviews, vol. 60, no. 4-5, pp. 598–607, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. V. P. Torchilin, “Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers,” Advanced Drug Delivery Reviews, vol. 60, no. 4-5, pp. 548–558, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. A. T. Jones, “Gateways and tools for drug delivery: endocytic pathways and the cellular dynamics of cell penetrating peptides,” International Journal of Pharmaceutics, vol. 354, no. 1-2, pp. 34–38, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. J. M. Gump and S. F. Dowdy, “TAT transduction: the molecular mechanism and therapeutic prospects,” Trends in Molecular Medicine, vol. 13, no. 10, pp. 443–448, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Brooks, B. Lebleu, and E. Vivès, “Tat peptide-mediated cellular delivery: back to basics,” Advanced Drug Delivery Reviews, vol. 57, no. 4, pp. 559–577, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Mishra, G. H. Lai, N. W. Schmidt et al., “Translocation of HIV TAT peptide and analogues induced by multiplexed membrane and cytoskeletal interactions,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 41, pp. 16883–16888, 2011. View at Publisher · View at Google Scholar
  8. B. J. Doranz, K. Grovit-Ferbas, M. P. Sharron et al., “A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor,” Journal of Experimental Medicine, vol. 186, no. 8, pp. 1395–1400, 1997. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Lapidot, A. Peled, A. Berchanski et al., “NeoR6 inhibits HIV-1-CXCR4 interaction without affecting CXCL12 chemotaxis activity,” Biochimica et Biophysica Acta, vol. 1780, no. 6, pp. 914–920, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Lee-Huang, V. Maiorov, P. L. Huang et al., “Structural and functional modeling of human lysozyme reveals a unique nonapeptide, HL9, with anti-HIV activity,” Biochemistry, vol. 44, no. 12, pp. 4648–4655, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. P. Bergman, L. Walter-Jallow, K. Broliden, B. Agerberth, and J. Söderlund, “The antimicrobial peptide LL-37 inhibits HIV-1 replication,” Current HIV Research, vol. 5, no. 4, pp. 410–415, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. F. C. Krebs, S. R. Miller, M. L. Ferguson, M. Labib, R. F. Rando, and B. Wigdahl, “Polybiguanides, particularly polyethylene hexamethylene biguanide, have activity against human immunodeficiency virus type 1,” Biomedicine and Pharmacotherapy, vol. 59, no. 8, pp. 438–445, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. S. R. Passic, M. L. Ferguson, B. J. Catalone et al., “Structure-activity relationships of polybiguanides with activity against human immunodeficiency virus type 1,” Biomedicine and Pharmacotherapy, vol. 64, no. 10, pp. 723–732, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. N. Thakkar, V. Pirrone, S. Passic et al., “Persistent interactions between biguanide-based compound NB325 and CXCR4 result in prolonged inhibition of human immunodeficiency virus type 1 infection,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 5, pp. 1965–1972, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Thakkar, V. Pirrone, S. Passic et al., “Specific interactions between the viral coreceptor CXCR4 and the biguanide-based compound NB325 mediate inhibition of human immunodeficiency virus type 1 infection,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 2, pp. 631–638, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Lozenski, T. Kish-Catalone, V. Pirrone et al., “Cervicovaginal safety of the formulated biguanide-based human immunodeficiency virus type 1 (HIV-1) inhibitor NB325 in a murine model of microbicide application,” Journal of Biomedicine and Biotechnology, vol. 2011, Article ID 941061, 10 pages, 2011. View at Publisher · View at Google Scholar
  17. R. A. Wilkinson, S. H. Pincus, J. B. Shepard et al., “Novel compounds containing multiple guanide groups that bind the HIV coreceptor CXCR4,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 1, pp. 255–263, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. J. A. Martellini, A. L. Cole, N. Venkataraman et al., “Cationic polypeptides contribute to the anti-HIV-1 activity of human seminal plasma,” FASEB Journal, vol. 23, no. 10, pp. 3609–3618, 2009. View at Publisher · View at Google Scholar
  19. N. Venkataraman, A. L. Cole, P. Svoboda, J. Pohl, and A. M. Cole, “Cationic polypeptides are required for anti-HIV-1 activity of human vaginal fluid,” Journal of Immunology, vol. 175, no. 11, pp. 7560–7567, 2005. View at Google Scholar · View at Scopus
  20. H. Xiao, C. Neuveut, H. L. Tiffany et al., “Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 21, pp. 11466–11471, 2000. View at Google Scholar · View at Scopus
  21. M. Kuppuswamy, T. Subramanian, A. Srinivasan, and G. Chinnadurai, “Multiple functional domains of Tat, the trans-activator of HIV-1, defined by mutational analysis,” Nucleic Acids Research, vol. 17, no. 9, pp. 3551–3561, 1989. View at Google Scholar · View at Scopus
  22. A. K. Cardozo, V. Buchillier, M. Mathieu et al., “Cell-permeable peptides induce dose- and length-dependent cytotoxic effects,” Biochimica et Biophysica Acta, vol. 1768, no. 9, pp. 2222–2234, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. B. Ensoli, G. Barillari, S. Z. Salahuddin, R. C. Gallo, and F. Wong-Staal, “Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients,” Nature, vol. 345, no. 6270, pp. 84–86, 1990. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Nath, K. Psooy, C. Martin et al., “Identification of a human immunodeficiency virus type 1 Tat epitope that is neuroexcitatory and neurotoxic,” Journal of Virology, vol. 70, no. 3, pp. 1475–1480, 1996. View at Google Scholar · View at Scopus
  25. G. R. Campbell, E. Pasquier, J. Watkins et al., “The glutamine-rich region of the HIV-1 Tat protein is involved in T-cell apoptosis,” Journal of Biological Chemistry, vol. 279, no. 46, pp. 48197–48204, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Chauhan, A. Tikoo, A. K. Kapur, and M. Singh, “The taming of the cell penetrating domain of the HIV Tat: myths and realities,” Journal of Controlled Release, vol. 117, no. 2, pp. 148–162, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. B. Romani, S. Engelbrecht, and R. H. Glashoff, “Functions of Tat: the versatile protein of human immunodeficiency virus type 1,” Journal of General Virology, vol. 91, part 1, pp. 1–12, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. J. B. Rothbard, T. C. Jessop, R. S. Lewis, B. A. Murray, and P. A. Wender, “Role of membrane potential and hydrogen bonding in the mechanism of translocation of guanidinium-rich peptides into cells,” Journal of the American Chemical Society, vol. 126, no. 31, pp. 9506–9507, 2004. View at Publisher · View at Google Scholar · View at Scopus